Prognosis and Staging of AL Amyloidosis
© 2020 S. Karger AG, Basel..
The treatment options for systemic light chain amyloidosis (AL) are currently widening in an unprecedented way, brought about by an expanding arsenal of anti-myeloma therapy as well as by novel approaches to target toxic light chains and, most recently, deposited amyloid directly. In this context, accurate estimates of prognosis in AL, which allow for reliable patient advice and for example comparison of different therapies, are particularly important to clinicians. Some biomarkers and especially the genetic background of the underlying clonal disease as evaluated by interphase fluorescence in situ hybridization even have predictive value, enabling an appropriate treatment selection. Derived from the most frequently involved organs in AL, heart and kidney, this review focuses on overall survival and renal survival. A comprehensive overview and summary of reported prognostic factors and biomarkers in AL is given and the most important and validated factors are highlighted. Finally, established staging systems in AL as well as validated and perspective response criteria are presented.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:143 |
|---|---|
| Enthalten in: |
Acta haematologica - 143(2020), 4 vom: 09., Seite 388-400 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dittrich, Tobias [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 07.09.2020 Date Revised 07.09.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000508287 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311488021 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311488021 | ||
| 003 | DE-627 | ||
| 005 | 20231225142348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000508287 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1038.xml |
| 035 | |a (DE-627)NLM311488021 | ||
| 035 | |a (NLM)32570242 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dittrich, Tobias |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognosis and Staging of AL Amyloidosis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.09.2020 | ||
| 500 | |a Date Revised 07.09.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 S. Karger AG, Basel. | ||
| 520 | |a The treatment options for systemic light chain amyloidosis (AL) are currently widening in an unprecedented way, brought about by an expanding arsenal of anti-myeloma therapy as well as by novel approaches to target toxic light chains and, most recently, deposited amyloid directly. In this context, accurate estimates of prognosis in AL, which allow for reliable patient advice and for example comparison of different therapies, are particularly important to clinicians. Some biomarkers and especially the genetic background of the underlying clonal disease as evaluated by interphase fluorescence in situ hybridization even have predictive value, enabling an appropriate treatment selection. Derived from the most frequently involved organs in AL, heart and kidney, this review focuses on overall survival and renal survival. A comprehensive overview and summary of reported prognostic factors and biomarkers in AL is given and the most important and validated factors are highlighted. Finally, established staging systems in AL as well as validated and perspective response criteria are presented | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Prognostic factors | |
| 650 | 4 | |a Staging systems | |
| 650 | 4 | |a Survival | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Kimmich, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Hegenbart, Ute |e verfasserin |4 aut | |
| 700 | 1 | |a Schönland, Stefan O |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta haematologica |d 1948 |g 143(2020), 4 vom: 09., Seite 388-400 |w (DE-627)NLM000152889 |x 1421-9662 |7 nnns |
| 773 | 1 | 8 | |g volume:143 |g year:2020 |g number:4 |g day:09 |g pages:388-400 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000508287 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 143 |j 2020 |e 4 |b 09 |h 388-400 | ||